Sanofi to review its new eczema drug amlitelimab
Corvus shares nearly triple on positive data for eczema pill
An immune drug developer raises $50M to finance its eczema drug testing
Nektar sees silver lining as autoimmune drug ‘narrowly’ misses in alopecia study
J&J eyes $100B in sales amid gains for cancer, immune drugs
Alumis soars as TYK2 drug hits mark in psoriasis trials
Galapagos TYK2 drug hits goal in one trial, misses in another
Takeda says $4B TYK2 drug succeeds in large psoriasis studies
Pfizer-backed Priovant scores again with fast-rising brepocitinib in midstage study
May 19th - 21st 2026 | Amsterdam, Netherlands